BACKGROUND: Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis. OBJECTIVE: We compared the KRAS and BRAF mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates. METHODS: DNA was extracted from 164 samples, and the mutation statuses of KRAS and BRAF were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate. RESULTS: Among the 164 CRC cases, KRAS mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan-Meier survival analysis, KRAS mutation was not significantly associated with survival (p = 0.971). BRAF mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of BRAF mutations was significantly decreased (p = 0.02). CONCLUSIONS: The presence of KRAS mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in BRAF-mutated CRC patients. Therefore, BRAF mutation could be an important prognostic factor in CRC patients.
BACKGROUND: Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis. OBJECTIVE: We compared the KRAS and BRAF mutation status of CRCpatients with their clinicopathological characteristics and examined the effect of mutation status on survival rates. METHODS: DNA was extracted from 164 samples, and the mutation statuses of KRAS and BRAF were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate. RESULTS: Among the 164 CRC cases, KRAS mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan-Meier survival analysis, KRAS mutation was not significantly associated with survival (p = 0.971). BRAF mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of BRAF mutations was significantly decreased (p = 0.02). CONCLUSIONS: The presence of KRAS mutation did not correlate with the various clinicopathological factors of CRCpatients or the survival rate. However, the survival rate was reduced in BRAF-mutated CRCpatients. Therefore, BRAF mutation could be an important prognostic factor in CRCpatients.
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule Journal: Ann Oncol Date: 2010-05-25 Impact factor: 32.976
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson Journal: Nature Date: 1983 Aug 11-17 Impact factor: 49.962
Authors: H Bouzourene; P Gervaz; J P Cerottini; J Benhattar; P Chaubert; E Saraga; S Pampallona; F T Bosman; J C Givel Journal: Eur J Cancer Date: 2000-05 Impact factor: 9.162
Authors: Karin Fransén; Maria Klintenäs; Anna Osterström; Jan Dimberg; Hans-Jürg Monstein; Peter Söderkvist Journal: Carcinogenesis Date: 2003-12-19 Impact factor: 4.944
Authors: Amy J French; Daniel J Sargent; Lawrence J Burgart; Nathan R Foster; Brian F Kabat; Richard Goldberg; Lois Shepherd; Harold E Windschitl; Stephen N Thibodeau Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Yang Guan; Yi Zhang; Li Xiao; Jie Li; Ji-Ping Wang; Mahendra D Chordia; Zhong-Qiu Liu; Leland W K Chung; Wei Yue; Dongfeng Pan Journal: Mol Pharm Date: 2016-12-16 Impact factor: 4.939
Authors: Daeyoun David Won; Jae Im Lee; In Kyu Lee; Seong-Taek Oh; Eun Sun Jung; Sung Hak Lee Journal: BMC Cancer Date: 2017-06-05 Impact factor: 4.430
Authors: Orsolya Módos; Henning Reis; Christian Niedworok; Herbert Rübben; Attila Szendröi; Marcell A Szász; József Tímár; Kornélia Baghy; Ilona Kovalszky; Tomasz Golabek; Piotr Chlosta; Krzysztof Okon; Benoit Peyronnet; Romain Mathieu; Shahrokh F Shariat; Péter Hollósi; Péter Nyirády; Tibor Szarvas Journal: Oncotarget Date: 2016-06-28